Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Inventory Average (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed Inventory Average for 7 consecutive years, with $17.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Inventory Average fell 6.76% to $17.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.1 million, a 6.76% decrease, with the full-year FY2025 number at $15.9 million, changed 0.25% from a year prior.
  • Inventory Average was $17.1 million for Q4 2025 at Akebia Therapeutics, down from $17.7 million in the prior quarter.
  • In the past five years, Inventory Average ranged from a high of $52.9 million in Q1 2021 to a low of $17.1 million in Q4 2023.
  • A 5-year average of $27.8 million and a median of $21.6 million in 2023 define the central range for Inventory Average.
  • Peak YoY movement for Inventory Average: crashed 62.88% in 2021, then grew 19.58% in 2024.
  • Akebia Therapeutics' Inventory Average stood at $35.2 million in 2021, then decreased by 4.99% to $33.4 million in 2022, then plummeted by 48.91% to $17.1 million in 2023, then grew by 7.63% to $18.4 million in 2024, then fell by 6.76% to $17.1 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Inventory Average are $17.1 million (Q4 2025), $17.7 million (Q3 2025), and $18.2 million (Q2 2025).